beta2-microglobulin serum level is not a marker of disease activity in multiple sclerosis
- 1 July 2004
- journal article
- Published by Wiley in European Journal of Neurology
- Vol. 11 (7) , 455-460
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 yearsBrain, 2003
- A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2001
- Interferon-β1a administration results in a transient increase of serum amyloid A protein and C-reactive protein: comparison with other markers of inflammationImmunology Letters, 2001
- Multiple Sclerosis: Fas Signaling in Oligodendrocyte Cell DeathJournal of Experimental Medicine, 1996
- Time series for modelling counts from a relapsing‐remitting disease: Application to modelling disease activity in multiple sclerosisStatistics in Medicine, 1994
- Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines.Journal of Neurology, Neurosurgery & Psychiatry, 1991
- Beta-2-Microglobulin Levels in the Cerebrospinal Fluid: Their Value as a Disease MarkerEuropean Neurology, 1991
- Increased level of cerebrospinal fluid β2-microglobulin is related to neurologic impairment in multiple sclerosisActa Neurologica Scandinavica, 1988
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- THE SMALL SUBUNIT OF HL-A ANTIGENS IS ß2-MICROGLOBULINJournal of Experimental Medicine, 1973